EUCTR2016-003817-80-FR进行中（未招募）1 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80 mg and 120mg after 12 Weeks of Treatment in Patients With Primary Biliary Cholangitis and Inadequate Response to Ursodeoxycholic Acid
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Genfit SA
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Must have provided written informed consent (IC)
- •2. Males or females 18 to 75 years of age
- •3. Definite or probable PBC diagnosis as demonstrated by the presence of at least 2 of the following 3 diagnostic factors:
- •o History of elevated ALP levels for at least 6 months
- •o Positive Anti-Mitochondrial Antibodies (AMA) titers (> 1/40 on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay [ELISA]) or positive PBC-specific antinuclear antibodies
- •o Liver biopsy consistent with PBC
- •4. ALP = 1.67x upper limit of normal (ULN) (‘inadequate response to UDCA’)
- •5. Taking UDCA for at least 12 months (stable dose for = 6 months) prior to screening visit
- •6. Contraception: Females participating in this study must be of non-childbearing potential or must be using highly efficient contraception for the full duration of the study and for 1 month after the end of treatment, as described below:
- •a) Cessation of menses for at least 12 months due to ovarian failure
- •b) Surgical sterilization such as bilateral oopherectomy, hysterectomy, or medically documented ovarian failure
- •c) Using a highly effective non-hormonal method of contraception (bilateral tubal occlusion, vasectomised partner or intra-uterine device)
- •d) Double contraception with barrier and highly effective hormonal method of contraception (oral, intravaginal or transdermal combined estrogen and progestogen hormonal contraception associated with inhibition of ovulation, oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation or intrauterine hormone-releasing system). The hormonal contraception must be started at least one month prior to randomization.
- •7. Must agree to comply with the trial protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •1. History or presence of other concomitant liver diseases including:
- •Positive hepatitis B surface antigen (HBsAg) at Screening
- •Positive HCV RNA (tested for in case of known cured HCV infection, or positive HCV Ab at screening)
- •Alcoholic liver disease
- •Primary sclerosing cholangitis (PSC)
- •Definite autoimmune hepatitis (AIH), or ‘AIH-PBC overlap syndrome’; the existence of AIH is defined as continuing use of budesonide or other systemic corticosteroid therapy, and/or azathioprine, and/or other immunosuppressive therapy following an historical AIH diagnosis (EASL 2015). ‘AIH-PBC overlap syndrome’ is based upon fulfilment of the ‘Paris criteria’ (Chazouillères 1998) for both AIH (ALT =5x ULN; IgG =2x ULN or smooth muscle antibody; interface hepatitis), and PBC(ALP =2x ULN; AMA, and non-suppurative bile duct injury/destruction), requiring corticosteroid therapy for disease management, either currently or in the past.
- •Biopsy confirmed Nonalcoholic Steatohepatitis (NASH)
- •Known history of alpha-1 antitrypsin deficiency, or other metabolic forms of chronic liver disease
- •Gilbert's Syndrome (due to interpretability of bilirubin levels)
- •2. Screening CPK > ULN
- •3. Screening ALT or AST > 5 ULN
- •4. Screening total bilirubin > 2 ULN
- •5. Screening serum creatinine > 1.5 mg/dl and eGFR < 60 mL/min/1.73 m2, at screening
- •6. Significant renal disease, including nephritic syndrome, chronic kidney disease
- •7. Patients with moderate or severe hepatic impairment (defined as Child-Pugh class B, C)
- •8. Platelet count <150 X 10 3/microliter
- •9. Albumin <3.5 g/dL
- •10. Presence of clinical complications of PBC or clinically significant hepatic decompensation, including:
- •Current Model for End Stage Liver Disease (MELD) score = 15; current placement on a liver transplant
- •list, or history of undergoing liver transplantation
- •Any record of complications of cirrhosis and/or portal hypertension such as:
- •o Gastroesophageal variceal bleeding and endoscopic therapy and/or transjugular intrahepatic portosystemic shunt [TIPS] insertion
- •o Ascites formation requiring intervention, e.g. diuretic therapy
- •o Spontaneous bacterial peritonitis
- •o Hepatic encephalopathy
- •o Confirmed or suspected hepatocellular carcinoma
- •11. Hepatorenal syndrome (type I or II) Administration of the following medications is prohibited as specified below:
- •From pre-randomization to EOT or V5 visit : indomethacin
- •2 months preceding screening and throughout the trial (up to the last study visit): fibrates or obeticholic acid, thiazoledinediones, glitazones
- •3 months prior to screening and throughout the trial (up to the last study visit): azathioprine, colchicine,
- •cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline; budesonide and other chronic
- •systemic corticosteroids; and potentially hepatotoxic drugs (including a-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)
- •12 months prior to inclusion visit and throughout the trial (up to the last study visit): antibodies or immunotherapy directed against interleukins or other cytokines or chemokines
- •NOTE : Anti-pruritus treatment, including rifamycin, is allowed if prescribed for at least 6 months prior
- •to screening, and on stable dose at least 3 months prior to screening. and continues at the same dose throughout the study
- •12. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy
- •test), or lactating
- •13. Known history of human
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic HyperplasiaPatients with lower urinary tract symptoms due to Benign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2005-004281-17-CZAllergan Inc.350
未知
3 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled PhaseIII Study to Evaluate the Efficacy and Safety of OVF in Opioid tolerant Patients With Cancer and Breakthrough Pain.JPRN-jRCT2080221194Taiho Pharmaceutical Co., Ltd.
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate theSafety and Antiretroviral Activity of MK-0518 in Combination With an OptimizedBackground Therapy (OBT), Versus Optimized Background Therapy Alone, in HIVInfected Patients With Documented Resistance to at Least 1 Drug in Each of the 3Classes of Licensed Oral Antiretroviral Therapies - Safety, PK, and Efficacy of MK-0518 plus OBT vs OBT Alone in HIV+nspecified human immuno-deficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162EUCTR2005-005127-34-PTMerck Sharp & Dohme, Lda.366
进行中（未招募）
1 期
A global study completed at hospitals in US, Europe & Asia using an investigational drug (Perampanel) to research its safety & effectiveness in patients who are at least 2 years of age with Lennox-Gastaut SyndromeSeizures associated with Lennox-Gastaut Syndrome (LGS)MedDRA version: 20.0Level: PTClassification code 10048816Term: Lennox-Gastaut syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-002321-35-PLEisai Limited70
进行中（未招募）
不适用
A Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Patients with Type 2 Diabetes with not very well controlled high blood pressure taking medicine called Angiotensin-Converting Enzyme Inhibitor (ACEI)or Angiotensin Receptor Blocker (ARB) and Medication to reduce high Blood Preassure in addition. The Phase 3 Trial is carried out at several sites and neither patients nor doctors know which study treatment (medication in different strength or dummy treatment) they are assigned to.Type 2 diabetes with inadequate glycemic control and inadequately controlled hypertensionMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10066860Term: Uncontrolled hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2010-019798-13-IEBristol Myers Squibb International Corporation22